Effects of Antiepileptic Drugs on Lipids, Homocysteine, and C-Reactive Protein. Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Sperling MR. Ann Neurol 2009;65:448-456. OBJECTIVE: The widely prescribed anticonvulsants phenytoin and carbamazepine are potent inducers of cytochrome P450 enzymes, which are involved in cholesterol synthesis. We sought to determine whether these drugs have an effect on cholesterol and other serological markers of vascular risk.
( p < 0.05). Results were similar whether patients were switched to lamotrigine or levetiracetam. INTERPRETATION: Switching epilepsy patients from the enzyme-inducers carbamazepine or phenytoin to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinically significant amelioration in several serological markers of vascular risk. These findings suggest that phenytoin and carbamazepine may substantially increase the risk for cardiovascular and cerebrovascular disease.
COMMENTARY
O ne major distinctive feature of most new antiepileptic drugs is that they do not interact with cytochrome P450 (CYP450) liver enzymes, while in contrast, the classic antiepileptic drugs carbamazepine, phenytoin, phenobarbital, and primidone are potent inducers and valproate is an inhibitor of these enzymes. The most recognized disadvantage of enzyme induction or inhibition is interaction with other pharmacological therapies. In particular, enzyme inducers can decrease serum concentrations and the therapeutic efficacy of medications metabolized by the CYP450 enzymes. The list of influenced medications includes antiepileptic drugs as well as various nonseizure medications, including anticoagulants, antibiotics, antineoplastic agents, immunosuppressants, and statins. For example, when carbamazepine is initiated for a patient also receiving warfarin for anticoagulation, the warfarin metabolism is augmented and its therapeutic efficacy is reduced to the point that the dose of warfarin must be increased to maintain the same level of anticoagulation. Similarly, carbamazepine and phenytoin increase the metabolism of valproate to the extent that it can be very difficult to reach the target valproate serum level, even with very high doses. The increased breakdown of medications not only elevates inactive metabolites but occasionally also may add to the production of toxic byproducts. For instance, the concomitant use of carbamazepine and valproate increases valproate toxic metabolites and may play a role in the onset of idiosyncratic hepatitis and pancreatitis (1) .
As more has become known about the CYP450 enzyme system, it is apparent that the system has a multitude of other functions, including the synthesis and breakdown of endogenous substances, such as vitamin D, steroid sex hormones, cholesterol, and other lipids (2) ; accordingly, the chronic use of enzyme-inducing antiepileptic drugs has been associated with reduced bone density (3, 4) , altered sex hormone levels (5, 6) , and changes in lipid profile (7) .
The current study by Mintzer and colleagues focused on the lipid profile as well as other markers of vascular disease, including C-reactive protein and homocysteine levels, and evaluated the effect of switching from the enzyme-inducers, carbamazepine and phenytoin, to the non-enzyme-inducers, lamotrigine, and levetiracetam. The observation that total cholesterol, atherogenic non-high-density cholesterol, triglycerides, and C-reactive protein were all lowered by switching from either of the enzyme-inducing to the noninducing Epilepsy Currents, Vol. 9, No. 6 (November/December) 2009 pp. 158-159 Wiley Periodicals, Inc. C American Epilepsy Society medications strongly suggests that reversal of enzyme induction is the mechanism underlying this improvement. However, carbamazepine and phenytoin also had distinct effects on lipoprotein(a) and homocysteine, indicating that nonspecific enzyme induction alone is not responsible for all the changes.
One important observation in the study by Mintzer et al. is that there was considerable heterogeneity among individuals with respect to changes in lipid profile after switching to lamotrigine or levetiracetam. Among the 36 patients, 3 had an increase in total cholesterol and 6 had an increase in atherogenic cholesterol after stopping enzyme-inducing medications. Furthermore, Mintzer and colleagues point out that studies of Finnish populations failed to show that enzyme-inducing antiepileptic drugs increased cholesterol at all (8) . Mintzer et al. speculated that this finding reflects pharmacogenetic heterogeneity as a result of allelic variants of the CYP450 genes. Just as certain individuals are genetically predisposed to the toxicity of certain medications, others may be predisposed to unfavorable changes in lipid profile from induction of the CYP450 enzymes. With advances in pharmacogenetics, individuals at risk for adverse changes in lipid profile potentially may be identified with genetic testing.
Mintzer et al. argue that treatment with phenytoin and carbamazepine may increase the risk for cardiovascular and cerebrovascular disease. In support of their contention, they cited epidemiological data indicating a greater prevalence of cardiovascular and cerebrovascular disease in epilepsy patients than in the general population. The authors recommended that epilepsy treatment start with a non-enzyme-inducing drug. While there are many reasons to select a non-enzyme-inducing antiepileptic drug as first-line therapy, it seems advisable to await additional evidence for a link between enzyme induction and cardiovascular risk before excluding enzyme-inducing drugs on that basis alone. As a result of the complexity and extensive role of the CYP450 system, enzyme induction may have additional unforeseen influences. In addition, it also is not known if the new nonenzyme-inducing antiepileptic drugs affect cardiovascular risk through mechanisms other than the CYP450 system. Caution can be engendered from the unpredictable relationship between enzyme induction and alteration of bone metabolism. Use of an enzyme-inducing antiepileptic drug was expected to be associated with reduced bone density, as a result of hypermetabolism of vitamin D. Yet, when a careful study was done, bone den-sity also was reduced by the non-enzyme-inducing antiepileptic drug valproate (9) , and there was surprisingly no difference between carbamazepine and the much less enzyme-inducing drug, oxcarbazepine, with respect to vitamin D level and measures of bone turnover (10) . The link between enzyme induction and cardiovascular risk will need to be explored further, with direct assessment of cardiovascular risk of patient groups receiving either enzyme-inducing or non-enzyme-inducing antiepileptic drugs in monotherapy. If enzyme-inducing antiepileptic drugs indeed, are associated with increased cardiovascular risk, their first-line use in epilepsy therapy will need to be strongly reassessed. sulci harboring them is difficult due to the complexity of brain convolutions. Our purpose was to elucidate and quantify the spatial relationship between FCD lesions and brain sulci using automated sulcal extraction and morphometry. We studied 43 consecutive FCD patients using high-resolution MRI. Lesions were classified into small and large using qualitative (detection on initial clinical assessment of conventional MRI) and quantitative (volume) criteria. Sulci were identified and labeled automatically using an algorithm based on a congregation of neural networks. Segmented FCD lesions and sulci were then simultaneously visualized in 3D. We measured mean and maximum depth of sulci related to each FCD and of the corresponding sulci in 21 healthy controls. In addition, we calculated sulcal depth within the FCD neighborhood. Twenty-one (21/43 = 49%) patients had small FCD lesions (volume range: 128-3093 mm (3)). Among them, 17 (81%) had been overlooked during initial radiological evaluation and were subsequently identified using image processing. Eighteen (18/21 = 86%) small FCD lesions were located at the bottom of a sulcus. Two others were related to the walls of two sulci and one was located at the crown of a gyrus. Mean and maximum depth of sulci related to the FCD was higher than that of the corresponding sulci in controls ( p < 0.008). Sulcal depth within lesional neighborhood had larger mean depth than that of the entire sulcus ( p < 0.0002). Evidence that small FCD lesions are preferentially located at the bottom of an abnormally deep sulcus may be used to direct the search for developmental abnormalities, particularly in patients in whom large-scale MRI features are only mildly abnormal or absent.
T he brain MRI may be assessed as normal on initial interpretation for as many as one-quarter of patients with pharmacoresistant epilepsy, who are referred for possible neurosurgical treatment (1). However, there is a significantly lower chance of postsurgical seizure freedom among patients for whom a relevant cerebral lesion has not been identified (2) . Fortunately, the ability to detect subtle lesions in patients with neocortical epilepsy is rapidly evolving, and more and more often they are being identified during the presurgical evaluation. Focal cortical dysplasia is the most common subtle lesion that is discovered, and, in one classification system (3), it is divided into two types: type 1-no dysmorphic neurons or balloon cells, but with dyslamination (type 1A) or dyslamination plus giant or immature neurons (type 1B); and type 2 (Taylor type)-dyslamination plus dysmorphic neurons, without balloon cells (type 2A) or with balloon cells (type 2B). Compared with type 1, patients with type 2 cortical dysplasia present at a younger age, have higher seizure frequencies, and are extratemporal (4). Type 1 dysplasia more frequently is found in adult patients and is located in the temporal lobe. While only a subset of patients with type 1 dysplasia will develop medically intractable epilepsy, type 2 is highly epileptogenic, with electrocorticography over the lesion usually showing continuous spiking (3) . When identified, complete resection of type 2 focal cortical dysplasia leads to good seizure control for most patients (4, 5) .
On occasion, focal cortical dysplasia is detected when careful reinspection of the fluid-attenuated inversion-recovery (FLAIR) MRI reveals a characteristic hyperintense funnelshaped subcortical zone that tapers towards the lateral ventricle, representing transmantle dysplasia (4) . Nonetheless, in many cases, the lesion cannot be detected on simple visual inspection. A number of investigators, including Besson et al., the authors of this study, have adapted a variety of image processing and analysis techniques to reveal more subtle abnormalities. One method is curvilinear reformatting, which creates planes that slice in a curved fashion parallel to the surface of the hemispheric convexity (6) . Since the sulci tend to be perpendicular to the cortical surface, the curvilinear plane cuts directly across them, which reduces effects of oblique sectioning and volume averaging when assessing cortical thickness (6) . Another approach is voxel-based morphometry, in which portions of the T1-weighted image are classified as gray matter, white matter, and CSF; the gray matter concentration map is subtracted from an averaged map of control images to identify areas of hyperintensity, which would presumably be areas of dysplasia (7) . Finally, textural analysis and morphological processing have been developed to map gray matter thickness and detect blurring of the gray-white matter junction that may also indicate a region of dysplasia (8) .
In the current paper, the three methods discussed were applied and coregistered with the results of image processing to extract the sulcal features. Small focal cortical dysplasia was Epilepsy Currents, Vol. 9, No. 6 (November/December) 2009 pp. 160-161 Wiley Periodicals, Inc. C American Epilepsy Society detected in many patients and was located primarily at the bottom of unusually deep sulci. The finding led to a proposed new class of type 2 focal cortical dysplasia termed, "bottom-of-sulcus dysplasia" (9) . The occurrence of this developmental malformation can be understood in terms of the Van Essen hypothesis that sulci are formed and shaped as a result of mechanical tension along axons in the white matter, with strongly connected regions pulled closer to each other during development (10) . The weak local cortical connectivity of the area of focal cortical dysplasia would result in the unopposed effects of longer corticothalamic connections pulling down on such a region during development, resulting in its ultimate location at the bottom of a deep sulcus.
This work by Besson et al. implies that subtle, bottomof-sulcus focal cortical dysplasia is not uncommon, but is a frequently overlooked cause of medically intractable epilepsy, and has profound implications for the surgical workup. Small, deep focal cortical dysplasia cannot be consistently and reliably detected by electrocorticography alone, because subdural grid or strip electrodes record from a distance at the crowns of gyri, and depth electrodes can only be appropriately placed with prior knowledge of the lesion location. Wider availability of improved imaging processing methods, such as those used by Besson et al., will be key to detecting bottom-of-the-sulcus focal cortical dysplasia. Identification of these lesions will mean that a significant subgroup of patients who were originally thought to be poor surgical candidates, with cryptogenic neocortical epilepsy, will be found instead to have this well-defined, surgically remediable focal cortical dysplasia syndrome. Among these patients, there was one episode of status epilepticus, three potentially serious electrocardiographic abnormalities, two cases of postictal psychosis, and four vertebral compression fractures during a generalized convulsion, representing 11% of patients with a recorded generalized tonic-clonic seizure. No deaths, transfers to the intensive care unit, falls, dental injuries, or pulmonary complications were recorded. An adverse event requiring intervention or interfering with normal activity occurred in 21% of these patients. Length of stay was not affected by occurrence of adverse events. CONCLUSION: Prolonged video-EEG monitoring is an acceptably safe procedure. Adverse events occur but need not result in substantial morbidity or increase length of hospitalization.
Appropriate precautions must be in place to prevent falls and promptly detect and treat seizure clusters, status epilepticus, serious electrocardiographic abnormalities, psychosis, and fractures.
N onmaleficence, to do no harm to patients, is the guiding principle of medical ethics and is epitomized by the well known, if often misattributed Latin phrase primum non nocere (1) . The principle is applied daily in clinical practice. Clinicians utilize an ever-expanding body of medical literature, along with their own clinical experiences, to provide a meaningful assessment of the risks, benefits, and alternatives for patients. In order to facilitate the care of patients with seizures or other undiagnosed paroxysmal events, video-EEG recording in an epilepsy monitoring unit is often recommended. In order to help these patients, physicians must first cause the very thing they are trying to treat: a seizure. Although the goals for admission vary depending on the clinical circumstances, they frequently include recording the patient's typical clinical event. In order to minimize the amount of time in the hospital, provocation techniques are often employed to elicit the symptoms. These techniques may include withdrawal or discontinuation of antiepileptic drugs, along with hyperventilation, sleep deprivation, and photic stimulation.
The potential hazards associated with seizures contribute to a higher standardized mortality rate for patients with epilepsy compared with the general population (2) (3) (4) . Numerous studies have examined the potential benefits of video-EEG monitoring for the patients, families, and the healthcare system in terms of long-term cost savings. However, there are relatively little data published on safety during epilepsy monitoring. Falls represent a preventable risk to patients in the hospital setting; although in one epilepsy monitoring unit, falls were 1.5 more times more frequent than in the neuroscience department at the same center (5) .
Noe and Drazkowski retrospectively reviewed the safety of video-EEG monitoring in a consecutive series of adult patients admitted to an epilepsy monitoring unit with a final diagnosis of either partial or generalized epilepsy. Of the 428 patients monitored with video-EEG, 149 met the study's inclusion criteria. Patients with a nondiagnostic study (14%), physiologic events (4%), or nonepileptic psychogenic seizures (24%) were excluded from the study; patients admitted for treatment of status epilepticus (3%) also were excluded.
Seizure-related injuries pose potential risks to patients in a monitoring unit. In this study, seizures were recorded in 109 of 149 patients. Two patients had prolonged seizures that responded to rescue medications. Seizure clusters, defined as three complex partial or generalized tonic-clonic seizures within a 24-h period, occurred in 23% of all the admitted patients, while the same type of clusters occurring within a 4-h timeframe was seen in 9%. None of the patients required transfer to an intensive care setting. However, four patients developed vertebral compression fractures following a generalized tonic-clonic seizure; however, all four had confirmed osteopenia, and two had evidence of chronic compression fractures. Little is known about the incidence of vertebral fractures in patients with epilepsy. The authors note that in the time following the study period, from January 2007 until their findings were published in 2009, only one additional patient with a vertebral fracture had been identified. There were no falls or fall-related injuries observed during the study period. Cardiac abnormalities were detected in three patients, leading to inpatient cardiology consultations. Although postictal psychosis has been reported in up to 6.7% Epilepsy Currents, Vol. 9, No. 6 (November/December) 2009 pp. 162-163 Wiley Periodicals, Inc. C American Epilepsy Society of patients with seizures and poses a potential risk for patients (6) , only two (1.8%) patients developed postictal psychosis.
The authors demonstrate that there was excellent overall safety during video-EEG monitoring, with continuous observation of both the video and EEG by a trained technologist. However, the level of monitoring provided varies among institutions, thereby limiting the applicability of these findings to other centers. An international survey of 78 medical centers and 42 respondents revealed that epilepsy monitoring units ranged in size from 1 to 20 beds. In this survey, 32 of 42 units (77%) reported that they have continuous patient surveillance, either by epilepsy monitoring unit staff or by family and friends of the patient (7) . Many potential sources of injury (e.g., falls, agitation, or confusional states) identified in the study by Noe and Drazkowski as well as reviewed by Sanders et al. can be mitigated by vigilant monitoring and early intervention (8) . The guidelines of the National Association of Epilepsy Centers "highly recommend" continuous observation in the inpatient epilepsy monitoring unit setting (9) . One could hypothesize that centers with lower levels of patient monitoring may have higher rates of falls and seizure-related injuries.
As the technology of video-EEG systems continues to evolve, improved surveillance techniques have become available, including integrated pulse oximetry, superior video capabilities (e.g., increased resolution allowing for larger and clearer images of the patient), and improved automated detection algorithms. Although technology can certainly enhance safety efforts, accurate data regarding safety and interventions still need to be compiled. An expert consensus panel on monitoring unit safety occurred at a symposium during the 2008 American Epilepsy Society's Annual Meeting, with presentations addressing a wide range of potential safety issues. This systematic examination of epilepsy monitoring unit safety issues might foster a revisitation of the current standards and ultimately, improve safety for a set-ting with such inherent risks, given the need to capture seizures. Yet, the study by Noe and Drazkowski illustrates that it is possible for monitoring to be performed in a safe manner, albeit not risk-free. As the healthcare system in the United States begins to focus on quality and outcome measures in an effort to curtail costs, the epilepsy community can be proactive in evaluating the risks and benefits of video-EEG monitoring. Most importantly, safety measures need to be identified and utilized so that the primary tenet of our profession is maintained: 
I t is axiomatic that having more than one unprovoked seizure is necessary to make the diagnosis of epilepsy. In the past, the clinical context in which a first seizure occurred was among the factors taken into accounted when conferring the diagnosis of epilepsy. Thus, seizures that were temporally related to a recent stroke, metabolic deficiency, or other malady may have been discounted and would not necessarily have led to an epilepsy diagnosis. However, in 2005, the International League against Epilepsy revised the definition of epilepsy such that even a single seizure was sufficient to constitute a diagnosis of epilepsy (1) . Essentially, the revised criteria could be construed to mean that all first seizures are created equally-the clinical circumstances did not matter. It is with that backdrop that Hesdorffer and colleagues sought to evaluate whether all first seizures indeed carried an equivalent prognosis.
In order to study this issue, the investigators identified patients who either had had a stroke, traumatic brain injury, or CNS infection. They then assessed whether individual first seizures were directly related to the acute phase of those etiologies or whether the seizure occurred subsequent to the acute phase, thereby creating two subgroups for analysis. If the seizure occurred within a 7-day time period of the insult, the patient was placed into a symptomatic category, as part of the acute phase group. The second group was made up of all patients whose seizures occurred outside of the 1-week acute insult time window, and the seizures were deemed unprovoked. Seizure re-currence and patient mortality were compared between the two groups.
Hesdorffer et al. identified 410 individuals with one of the three neuropathological categories and a first seizure; 262 patients were placed in the "acute symptomatic seizure" and 148 in the "unprovoked seizure" group. The investigators found significant differences with regard to seizure recurrence and mortality. Individuals in the symptomatic group were almost nine times more likely to die in the first month compared with the unprovoked group, yet they were also much less likely to have a subsequent unprovoked seizure. In contrast, the unprovoked seizure groups were much more likely to have a subsequent unprovoked seizure regardless of the etiology, with 65% of the unprovoked seizure group having a subsequent event as compared to 18.7% of the acute symptomatic group. Therefore, the data suggest that even though individuals may present with the same type of neuropathology, there is clearly a difference in outcome between patients who have their seizure within a week of a stroke, traumatic brain injury, or CNS infection and those whose seizures occur in a temporally later timeframe. In essence, all seizures are not created equally.
Another study found a remarkably similar result in a distinctly different patient group and condition-neonates and neonatal seizures. In 2007, Ronan and colleagues applied the Mizrahi and Kellaway clinical seizure classification to population-based cohorts of neonatal seizures (2, 3) . They found that that the severity and timing of the pathologic process that influenced the presentation of seizures actually was the most important prognostic variable among these infants. In sum, they established that the clinical context in which a seizure occurs is the primary determinant in informing and guiding the Epilepsy Currents, Vol. 9, No. 6 (November/December) 2009 pp. 164-165 Wiley Periodicals, Inc. C American Epilepsy Society diagnosis and management of the neonates. It perhaps follows that the same may hold true for adult patients as well.
Hesdorffer and colleagues' analysis charts new territory in the fundamental concept of first seizures and epilepsy. This report is somewhat analogous to that of Kwan and Brodie, which proved to be seminal in demonstrating that not all epilepsy patients were the same, particularly, the recognition that some individuals presented with refractory epilepsy from the onset (4) . Similarly, the Hesdorffer et al. study shows that some first seizures are indeed epilepsy from the onset. Essentially, these authors present epidemiological facts that are in need of explanation, verification, and replication; ultimately, the outcome of such investigations may lead to an adjustment in the basic understanding of the condition. The findings also serve as a reminder of what eludes both basic and clinical science epilepsy research: the detection of more sensitive and specific biomarkers that can identify, from the onset, which individuals will be predisposed to recurrent, unprovoked seizures.
There are important treatment implications from this review that can be applied clinically. When a person presents with a first seizure, in order to provide accurate counsel to the patient, the clinician must take into account the underlying clinical context, both with regard to etiology and to whether that etiology is temporally related to the seizure. Patients without an overt lesion, perhaps, need to be followed more closely than individuals who present with a seizure in the setting of a stroke or traumatic brain injury, as this patient type would be somewhat akin to the unprovoked seizure group in the Hesdorffer et al. study. The importance of a thorough clinical history for patients with a first seizure cannot be stressed enough. Hopefully, in time, it will be possible to identify which seizures portend epilepsy and which are likely to have a more benign course.
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